GlassScriptPhysician profile
Marvin S Im
NPI 1154436665
$19,450.50
in general payments reported to CMS, 2019-2025
66 companies · $2,687 in 2025
The $2,687 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,982 · 2020: $2,705 · 2021: $3,034 · 2022: $2,536 · 2023: $2,852 · 2024: $2,654 · 2025: $2,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,027 · Education: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,026.58 |
| Education | $166.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,059.62 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $2,400.53 | 2019-2025 | |
| Pfizer INC. | $2,093.71 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,392.04 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amarin Pharma, INC. | $833.28 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $767.58 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $669.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Ibsa Pharma INC. | $572.12 | 2020-2025 | Tirosint, Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $552.62 | 2019-2025 | Trintellix |
| Amgen INC. | $486.16 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $473.15 | 2019-2023 | Spravato |
| Glaxosmithkline, LLC. | $442.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Antares Pharma, INC. | $430.78 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $371.72 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $346.18 | 2019-2022 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Im listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.